Hengrui Medicine (600276.SH): HRS-6209 conducts joint clinical trials with HRS-2189 and aromatase inhibitors approved for breast cancer.

Zh tng cijng APP xn, Hng ru yyo (600276.SH) fb gnggo, jnr, gngs j zgngs Shndng shngd yyo yuxin gngs shudo guji yopn jinsh gunl j (yxi jinchng "guji yojin j") hk zhf guny HRS-6209 jionng, HRS-2189 pin de "yow lnchung shyn pzhn tngzhsh", jing y jnr kizhn lnchung shyn. Jt wi HRS-6209 kizhn linh HRS-2189 h fngxing huz yzhj zhyng y rxin i de lnchung shyn.